CK1δ as a potential therapeutic target to treat bladder cancer

Bladder cancer is the second most common genitourinary malignancy in the world. However, only immune-checkpoint inhibitors and erdafitinib are available to treat advanced bladder cancer. Our previous study reported that 4-((4-(4-ethylpiperazin-1-yl) phenyl)amino)-N-(3,4,5-trichlorophenyl)-7H-pyrrolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Chen, Chen, Mei-Chuan, Hsieh, Tsung-Han, Liou, Jing-Ping, Chen, Chun-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185098/
https://www.ncbi.nlm.nih.gov/pubmed/32282334
http://dx.doi.org/10.18632/aging.102966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185098/
https://www.ncbi.nlm.nih.gov/pubmed/32282334
http://dx.doi.org/10.18632/aging.102966

Ejemplares similares